CRMD:NASDAQCorMedix Inc. Analysis

CorMedix (CRMD) is trading at roughly $8.7, far below its DCF‑derived fair value of $55, implying a potential upside of over 70% and a stark valuation gap versus the industry PE average of 24× (CRMD PE is ~4×). The company posted Q1 net revenue of $127.4 M and net income of $38.6 M, with adjusted EBITDA of $70 M, underscoring strong profitability; margins are exceptionally high (gross margin ~92%, operating margin ~50%, profit margin ~45%) and ROE sits at an eye‑popping 65%. Technicals are mixed: the 20‑day SMA (8.48) sits just below the current price, the MACD histogram is slightly negative with a “bearish” signal, and RSI is at 59, indicating no immediate overbought condition, while volume is trending upward and price is near the identified support of $7.77. Beta of 1.37 and 30‑day volatility of 38% point to pronounced price swings, yet the company’s cash position ($178 M) comfortably exceeds its debt ($147 M), giving a solid balance‑sheet cushion. Overall, the fundamentals are compelling, but the biotech sector’s regulatory and execution risks keep the stock’s risk profile elevated.